Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Alendronate Gel with PRF in Chronic Periodontitis
NCT06856369Phase 4Active, not recruiting
- Sponsor
- Bahria University
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin 1% gel and alendronate in chronic periodontitis (3 arms), sponsored by Bahria University. Primary endpoints: Reduction in intra-bony defect depth at 12 months, Reduction in vertical bone loss at 12 months and 2 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
metformin 1% gelalendronate
03
Conditions
chronic periodontitis
Beyond the preview
Go deeper on NCT06856369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856369.